Building An AM Quality Data Backbone That Makes AI Credible
Visionstate Announces $750,000 financing to Support International Expansion and Strategic Growth
Local AI Registry Launches First Public Registry of AI Business Recommendations
Agereh Technologies to Attend 2026 ACI-NA Annual Conference & Exhibition in Philadelphia
FlameProxies Launches Residential Proxy Network Across 180 Countries Without Contract Commitments
Lead product candidate, ZB001, has first-in-class potential in China for Thyroid Eye Disease Rapidly advancing…
RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S…
Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS)…
Press Release Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone…
For the First Time Scientific Data From a Certified Canadian Laboratory Answers This Fundamental Question….
Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by…
With eight new configurations, cobas pro® integrated solutions offers labs greater flexibility to ramp up…
NEW HAVEN, Conn., March 22, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the…
Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to…
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA),…
EDISON, N.J., March 22, 2021 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical…
Blood Sugar Blaster is a sugar-regulating supplement that seeks to prevent the user from catching…
Bagsværd, Denmark, 22 March 2021 – Novo Nordisk today announced that the US Food and…
Company announcement – No. 16 / 2021 Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon)…
FOSTER CITY, Calif., March 22, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation…
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)…
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and…
SANTA MONICA, Calif., March 22, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a…
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology…
YONKERS, N.Y., March 22, 2021 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…